Liquid Biopsy Market: Current Analysis and Forecast (2025-2033)

Liquid Biopsy Market Size & Forecast

The Liquid Biopsy Market was valued at approximately USD 8.1 billion in 2024 and is expected to grow at a substantial CAGR of around 13.5% during the forecast period (2025-2033), owing to the rising demand for non-invasive cancer diagnostics.

Liquid Biopsy Market Analysis

Liquid biopsy is a non-invasive procedure that enables doctors to identify information regarding the tumor using a blood sample. This technique is mainly used to diagnose chronic diseases such as cancer. It is also used to monitor the effect of treatment on cancer patients multiple times. Liquid biopsy will take a prominent position in cancer-related research and investigation. The liquid biopsy is rapidly substituting conventional tumor biopsies. These are developed out of the need to acquire the most amount of molecular information about cancer. This cancer information is obtained with the least amount of surgical invasion. Furthermore, the clinical trials for the development of these tests have given positive results and have led to larger-scale clinical trials demonstrating efficacy.

Liquid Biopsy Market Trends

This section discusses the key market trends influencing the various segments of the Liquid Biopsy market as identified by our research experts.

Integration of liquid biopsy with precision medicine

Cancer care improves through precision medicine as liquid biopsy provides personalized treatment strategies that base decisions on up-to-date genomic information. A liquid biopsy makes it possible to discover circulating tumor DNA (ctDNA) alongside other biomarkers through a single blood lab test to give health professionals vital tumor data without requiring surgical interventions. Cancer management becomes more patient-specific through targeted therapy selection, while response tracking and intervention changes become possible due to the data obtained from liquid biopsy.

Liquid Biopsy Market Industry Segmentation

This section provides an analysis of the key trends in each segment of the global liquid biopsy market report, along with forecasts at the global, regional, and country levels for 2025-2033.

The Lung Cancer Segment is Expected to Witness a Higher CAGR than the Liquid Biopsy Market.

Based on the cancer type, the global Liquid Biopsy market is categorized into lung, breast, colorectal, and prostate. The lung cancer segment accounted for the largest revenue share in 2024, owing to an increase in the prevalence of non-small cell lung cancer forms across the globe. Further, prostate cancer is expected to be the fastest growing segment during the forecast period as it is the most prevalent type of cancer and the second leading cause of death in North America.

The Assay Kits Segment Holds the Largest Share of the Market.

Based on product, the liquid biopsy market is segmented into assay kits, instruments. Among these, the assay kits segment is expected to be the fastest-growing segment in the product and services market during the forecast period. Factors such as the increasing demand for liquid biopsy tests, increasing applications of liquid biopsies, and the need for reliable and specific assays are expected.

North America has a significant share of the market in 2024.

North America holds the top position in the global market for liquid biopsy because it benefits from cutting-edge healthcare infrastructure and strong investments in precision medicine programs, combined with widespread cancer cases. The area experiences market expansion because healthcare facilities use non-invasive diagnostic methods and apply artificial intelligence (AI) and next-generation sequencing (NGS) technologies in the diagnosis of cancer. The U.S. maintains control over the largest market segment alongside Canada, where significant advancements in liquid biopsy procedures have been observed.

U.S. Dominates the North American Liquid Biopsy Market

The U.S. liquid biopsy industry shows fast development because of higher cancer rates combined with general medical practices moving towards patient-specific treatments and favorable regulatory approvals. Multi-cancer screening tests, along with other innovations for early cancer detection, have started gaining wider acceptance. The market experiences additional support through research and development investments from biotech firms, together with their healthcare institutions, working to improve diagnostic accuracy while enhancing accessibility of tests.

Liquid Biopsy Market Industry Competitive Landscape

The Liquid Biopsy market is competitive, with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, and mergers and acquisitions.

Top Liquid Biopsy Market Companies

Some of the major players operating in the market are Roche Diagnostics, Biocept, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., Menarini-Silicon Biosystems, Illumina, Inc., MDXhealth SA, Genomic Health, Inc. (Exact Sciences Corp.), Guardant Health Inc.

Recent Developments in the Liquid Biopsy Market

• In February 2024, Myriad Genetics, Inc. (US) entered into a definitive agreement to acquire select assets from Intermountain Health. These included assets from its Intermountain Precision Genomics (IPG) laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory.

• In January 2024, Natera, Inc. (US) acquired certain assets relating to non-invasive prenatal and carrier screening business from Invitae (US).

Liquid Biopsy Market Report Coverage

Reasons to Buy the Liquid Biopsy Market Report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at a glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional-level analysis of the industry.

Customization Options:

The global liquid biopsy market can be customized further as per the requirements or any other market segment. Besides this, UnivDatos understands that you may have your own business needs; hence, feel free to contact us to get a report that completely suits your requirements.